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Since endocrine disrupting chemicals (EDCs) may interfere with the endocrine system(s) of our body and
have an estrogenicity, we evaluated the effect(s) of bisphenol A (BPA) on the transcriptional levels of
altered genes in estrogen receptor (ER)-positive BG-1 ovarian cancer cells by microarray and real-time
polymerase-chain reaction. In this study, treatment with 17β-estradiol (E2) or BPA increased mRNA levels
of E2-responsive genes related to apoptosis, cancer and cell cycle, signal transduction and nucleic acid
binding etc. In parallel with their microarray data, the mRNA levels of some altered genes including
RAB31_MEMBER RAS ONCOGENE FAMILY (U59877), CYCLIN D1 (X59798), CYCLIN-DEPENDENT KINASE
4 (U37022), INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 4 (U20982), and ANTI-MULLERIAN
HORMONE (NM_000479) were significantly induced by E2 or BPA in this cell model. These results
indicate that BPA in parallel with E2 induced the transcriptional levels of E2-responsive genes in an
estrogen receptor (ER)-positive BG-1 cells. In conclusion, these microarray and real-time polymerase-
chain reaction results indicate that BPA, a potential weak estrogen, may have estrogenic effect by
regulating E2-responsive genes in ER-positive BG-1 cells and BG-1 cells would be the best in vitro model
to detect these estrogenic EDCs.
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Endocrine disrupting chemicals (EDCs) are environmentally
persistent chemicals that interfere with physiological endocrine
systems, adversely affecting hormone balance or disrupting
normal function in the organs that hormones regulate or
modulate [1,2]. Thus, EDCs can lead to serious detrimental
effects on reproductive and developmental processes of
humans, animals, and plants. Consequently, endocrine
disruption is a major health priority worldwide, particularly
for women and children [3,4]. EDCs include both natural
and man-made sources of estrogenic or androgenic chemicals
that have structures similar to estrogen or androgen and that
bind to estrogen receptors (ERs) or androgen receptors (ARs)
to interfere with the actions of endogenous steroid hormones
[3-6]. One class of EDCs is estrogenic phenol compounds,
octyl-phenol (OP), nonyl-phenol (NP), and bisphenol A (BPA),
which have chemical structure similar or distinct compared
to that of 17β-estradiol (E2) [5]. Some of these phenols are
breakdown products of surfactants, found in soaps and
detergents. Further, there is increasing evidence that EDCs
may interfere with the body’s complex and carefully regulate
hormonal system in diverse ways [4,7].
BPA, a compound used in polycarbonate and epoxy resins,
has been implicated as a potent risk factor for women’s health
[8]. BPA has been widely used in plastic products such as
drinking water containers, dental sealants, and coating
materials to prevent corrosion on the inner surface of canned
food. But BPA is released from plastic containers under normal
conditions of use and its leaching is facilitated at high
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temperature [9]. Exposure to BPA is even possible in contact
with swallowed dust [10] and exerts xenoestrogen action [11].
The mechanism by which EDCs interfere with endogenous
steroid hormones is not well understood. As many EDCs
are thought to affect sex hormone function, and therefore
reproduction, the findings in multi-generation animal studies
can provide strong evidence of the potential for endocrine
disruption [12]. In vitro methods for detection of estrogenic
compounds have been developed by several groups [13-
15]. The recent findings indicate that BPA, a weak estrogenic
EDC, activates the transcription factor, cAMP-responsive
element binding protein (CREB), via an alternative mechanism
involved in a non-classical membrane ER [16]. In addition,
useful biomarkers have been suggested to include the cell-
based endogenous genes [17,18]. Our previous research
utilized immature rats to detect estrogenic compounds
[5,6,19].
A better understanding of the cellular mechanisms
underlying the effect of EDCs is absolutely required in novel
ovarian cellular models expressing ERs. Based on our previous
studies, we further examined the altered gene expressions
following treatment with E2 or BPA by microarray and real-
time polymerase-chain reaction (PCR). This study would
provide the basis for further research into determining E2-
or BPA-induced gene expressions in highly E2-responsive
ovarian cancer cells.
Materials and Methods
Cell culture
An ovarian adenocarcinoma cell line, BG-1, is well known
for the expression of ERα [20]. This cell line was obtained
from Dr. K.S.
 Korach (National Institute of Environmental
Health Sciences,
 Research Triangle Park, NC, USA). It was
cultured in Dulbecco’s modified Eagle’s medium (DMEM)/
F12 mixture (Sigma-Aldrich, St. Louis, MO, USA) supplemented
with 10% fetal bovine serum (FBS; Hyclone Laboratories,
Logan, UT, USA), 100 U/mL penicillin G and 100 µg/mL
streptomycin (Life Technologies, Rockville, MD, USA) at 37
oC
in a humidified atmosphere of 5% CO2-95% air.
Treatment of BG-1 cells with E2 or BPA
After 70% confluence, BG-1 cells were treated with a
concentration of E2 (10
−7 M; Sigma-Aldrich) or BPA (10
−5
M; Sigma-Aldrich) at different time points (1, 8 and 24 h)
before harvest. Ethanol was added to the control media in
the same final solvent concentration (typically 0.1%).
Western blot analysis
Western blot assay was performed to identify the expression
of ERα and ERβ in BG-1 cells. Thirty µg of total protein
was run on a 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose
membrane. The membrane was Western-blotted using a
mouse monoclonal antibody for ERα (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and ERβ (Abcam, Cambridge, MA,
USA). Briefly, 1×10
6 cells were washed twice
 with ice-cold
phosphate-buffered saline (PBS) and lysed in 100 µL of in
ice-cold RIPA buffer [containing 1×
 PBS (pH 7.4), 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS,
  10 mg/mL
phenylmethylsulfonyl fluoride, 30 mg/mL aprotinin,
 and 10
mg/mL leupeptin] for 15 min on ice. The protein concentration
was determined using Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA). The protein solution
 was then subjected
to electrophoresis on a 10% SDS-PAGE and electrotransferred
to a nitrocellulose membrane (Hybond C; Amersham Pharmacia,
Oakville, ON, Canada). After washing three times with tri-
buffered saline-Tween (TBS-T; 0.1% Tween-20 in TBS) for
15 min, the signals were detected with horseradish peroxidase-
conjugated secondary antibody (Amersham Pharmacia) and
visualized using the ECL chemiluminescent system (Amersham
Pharmacia).
RNA isolation and cDNA microarray analysis
Total RNA was extracted with TriZol (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to manufacturer’s
suggested procedure, and purified using RNeasy total RNA
isolation kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. DNA was digested using an
RNase-free DNase set (Qiagen) during RNA purification. Total
RNA was quantified by spectrophotometer and its integrity
was assessed by running on a 0.8% agarose gel contained
diethyl pyrocarbonate (DEPC). To make cDNA from total
RNA for microarray analysis, the same quantity of each RNA
sample from the treated groups (n=4) or control groups (n=3)
was pooled. A cDNA microarray consists of approximate 8,000
cDNA spot including Incyte clones, housekeeping genes and
Arabidopsis thaliana (A. thaliana) DNA as controls. The PCR
was prepared according to the standard protocol and reaction
mixtures were subjected to be amplified at 35 cycles. The
primer pair used for amplification was overlap primer-1 (5'-
AAT TAA CCC TCA CTA AAG GG-3') and overlap primer-
2 (5'-GTA ATA CGA CTC ACT ATA GGG C-3'). The size
and amount of the PCR products were verified on 1% agarose
gel. The PCR products were purified by ethanol precipitation,Gene alteration by estrogen and BPA in ovarian cancer 101
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then resuspended in 15µL of hybridization solution (GenoCheck,
Sangrokgu, Korea), and spotted onto CMT-GAPS II silane slide
glass (Corning Life Sciences, Corning, NY, USA) with a pixsys
5500 arrayer (Cartesian Technologies Inc., Irvine, CA, USA)
using 16-Stealth Micro spotting pins. The printed slides were
processed according to CMT-GAPS II silane slide protocol.
Briefly, the spots were re-hydrated with 1× SSC for 1 min
and then DNA linked using a UV crosslinker (Stratagene Corp.,
La Jolla, CA, USA). The slides were soaked in the succinic
anhydride/sodium borate solution for 15 min with gentle
agitation and then transferred to a 95
oC water bath for 2
min. The slides were quickly transferred to 95% ethanol for
1 min and then dried using a centrifuge at 3,000 rpm for 20 sec.
Hybridization with fluorescent DNA probe
Eighty mL of probe mixture was heated at 95
oC for 3
min, and kept at 65
oC until use. Prior to hybridization, array
slide was incubated with prehybridization buffer containing
5× SSC, 0.1% SDS and 1% bovine serum albumin (BSA)
at 48
oC for 45 min. The slide was washed by dipping in
deionized water for 30 sec and dipped in isopropanol for
10 sec and spun dried in a centrifuge for 2 min. To hybridize
probe with array slide, probe was added to the denatured
array slide and cover slip was put on this slide. This slide
was transferred to hybridization chamber and incubated
overnight at 42
oC. The slide was washed twice with wash
buffer containing 1× SSC and 0.2% SDS at 42
oC and washed
two times with 1× SSC at room temperature. Slide was then
spun dried for 5 min. This microarray was scanned as described
by the scanner’s manufacturer. Microarray results were
categorized into several functional groups related with
apoptosis, cancer, cell cycle, growth factor/hormone, and signal
transduction.
Scanning and image analysis
Hybridized slides were scanned with the Axon Instruments
GenePix 4000B scanner and the scanned images were
analyzed with the software program GenePix Pro 5.1 (Axon
Instruments, Foster, CA, USA) and GeneSpring 7.1 (Sillicon
Genetics, Redwood, CA, USA). In order to allow algorithm
to eliminate all bad spots, no data points were eliminated
by visual inspection from the initial GenePix image. For signal
normalization, housekeeping genes (β-actin) and positive
control genes (A. thaliana genes) were spotted onto each
slide. The signals of these spots were used for normalization.
To filter out the unreliable data, spots with signal-to-noise
(signal-background-background SD) below 100 were not
included in the data. Data were normalized by global, lowess,
print-tip and scaled normalization for data reliability. Data
were sorted of above 2-fold altered genes using GeneSpring
7.1 (Sillicon Genetics, Redwood, CA, USA) and a hierarchical
clustering analysis was performed using Pearson correlation.
The statistical significance of differential expression was
assessed by computing a q-value for each gene. To determine
the q-value, we used a permutation procedure, and for each
permutation a two-sample t-statistic was computed for each
gene. The result was considered significant when the
logarithmic gene expression ratio of three independent
hybridizations was more than twofold the difference in the
expression level. The accuracy of microarray analysis in this
study was confirmed by real-time PCR.
Real-time PCR analysis
The standard curve
 was generated for a standard RNA
Table 1. Oligonucleotide sequences for real-time PCR
Gene name
Gene ID Sequences Expected size
RAB31_ MEMBER RAS ONCOGENE FAMILY 
U59877 Sense: 5’-GACCCAAGGGCGTGGTCCAC-3’ 160 bp
Antisense: 5’-ACATTTCCTGCCCCGCCCCC-3’
CYCLIN D1
X59798 Sense: 5’- GTAGCGTAGCGTGGCCGTGT-3’ 264 bp
Antisense: 5’- GCTGCAGGGCCGTTGGGTAG-3’ 
CYCLIN-DEPENDENT KINASE 4
U37022 Sense: 5’- TATGGTCGGGCCCTCTGCGTC-3’ 145 bp 145 bp
Antisense: 5’- CATTCCTGGGAAGGGACTGCACT-3’ 
INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 4
U20982 Sense: 5’-GTCCGGGCTAGGAAGTCCCTTTCT-3’ 369 bp 369 bp
Antisense: 5’-ACCGGCTCCCCCGGACTTTAT-3’ 
ANTI-MULLERIAN HORMONE 
NM_000479 Sense: 5’-GTGTTAGCGGTGGACCGCCC -3’ 256 bp 256 bp
Antisense: 5’-CCTCGAGTTCCGCGGATGGC -3’102 Kyung-A Hwang et al.
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preparation by serial dilution
 (1, 1/10, 1/100, 1/1000, and
0). A real-time PCR reaction was
 carried out in a 25 µL final
volume containing 12.5 µL
 of 2× premix (TaKaRa Bio, Otsu,
Japan), 0.3 µL
 of each of forward and reverse primers, 1 µL
of cDNA,
 and distilled water up to 25  µL. The oligonucleotide
sequences
 of primers were employed to detect various genes
as shown Table 1. PCR using the Smart Cycle System (TaKaRa
Bio) began with an
 initial denaturation at 95
oC for 30 sec.
Each of the 35 amplification
 cycles consisted of denaturation
at 95
oC for 5 sec, annealing
 at 55
oC for 15 sec, and extension
at 72
oC for 15 sec. Relative
 expression levels of each sample
were calculated based on the
  cycle threshold (Ct) and
monitored for an amplification curve.
 The PCR amplification
curves were evaluated by fluorescence
 of the double-stranded
DNA-specific dye, SYBR Green, versus
  the amount of
standardized PCR product. All gene expressions
  were
normalized to the expression of β-actin mRNA as a control.
Data analysis
Data were presented as the mean±SD. Data of real-time
PCR were analyzed by one-way ANOVA, followed by
Dunnettos test for two-pair comparisons. P<0.05 was
considered statistically significant.
Results
Confirmation of the expression of ERα and ERβ in
BG-1 cells
We confirmed the expression of ERα and ERβ by Western
blot analysis using ERα and ERβ specific antibodies in ovarian
cancer cells (BG-1). Both ERα and ERβ proteins were expressed
in BG-1 cells and detected in 68 kDa and 55 kDa, respectively
(Figure 1).
Altered gene expressions by E2 and BPA
Following individual treatment of BG-1 cells with E2 or
BPA, total RNAs from the cells were isolated and processed
by microarray analysis
 as described. Although the number
of genes whose expression was altered by E2 or BPA tested
is modest, there is substantial change in the gene expression
altered or modified
  by their exposure time. Increased
expression levels were shown in red and decreased expression
Figure 1. Expression of ERα and ERβ proteins in estrogen-
responsive ovarian cancer cells (BG-1). The protein was
isolated and prepared as described in the Materials and
Methods. The protein levels of ERα (68 kDa) and ERβ (55 kDa)
were detected by Western blot analysis by using an ERα or
ERβ monoclonal antibody in BG-1 cells.
Figure 2. Hierarchical clustering analysis. A hierarchical
clustering analysis was performed following treatments with
17β-estradiol (E2) and bisphenol A (BPA) at different time points
(1, 8, and 24 h) in BG-1 cells. Two-dimensional hierarchical
clustering was applied to the expression data from approximate
8.0 k genes, which showed significant changes in the balanced
differential expression. Increased expression levels were
shown in red and decreased expression levels shown in green.Gene alteration by estrogen and BPA in ovarian cancer 103
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levels shown green (Figure 2). The intensities of each spot
in this study were calculated and plotted. A clustering analysis
of typical of the three self vs. self comparisons was performed
in Figure 2, which showed that a more than two-fold change
would be necessary to overcome the intrinsic variability
introduced by the hybridization procedure. For this reason,
the data was further filtered to select for genes that showed
an absolute differential of at least two-fold or greater. The
change in the mRNA expressions of 51 genes was listed in
Table 2 and Table 3. Table 2 showed the common 33 genes
related apoptosis, cancer and cell cycle induced by E2 or
BPA treatment at different time points (1, 8, and 24 h). In
addition, altered gene expressions involved in signal transduction
and nucleic acid binding were listed following treatment with
E2 or BPA in Table 3. These genes might be universal estrogen-
responsive genes among various tissues. This compound
exhibited a reasonable hierarchical clustering; BPA resembled
to E2.
Confirmation of altered genes by real-time PCR
The expression patterns of several genes up-regulated by
E2 or BPA were confirmed to verify the results of the microarray
analysis using real-time PCR analysis. The expression levels
of altered genes including RAB31_MEMBER RAS ONCOGENE
FAMILY (U59877), CYCLIN D1 (X59798), CYCLIN-DEPEND
ENT KINASE 4 (U37022), INSULIN-LIKE GROWTH FACTOR-
BINDING PROTEIN 4 (U20982), and ANTI-MULLERIAN
HORMONE (NM_000479) were measured by microarray
analysis following treatment with E2 or BPA at 24 h in BG-
1 cells. In parallel with their microarray results, the mRNA
levels of these genes were significantly induced by E2 or
BPA at 24 h as shown in Figure 3. Among them, the most
increased gene was RAB31_MEMBER RAS ONCOGENE
FAMILY (U59877) as demonstrated. These results indicate
that BPA in parallel with E2 induced the transcriptional levels
of E2-responsive genes in an ER-positive BG-1 cells.
Discussion
EDCs are environmental chemicals that interfere with
physiological systems, adversely affecting hormone balance
(endocrine systems) or disrupting normal function in the organs
that hormones regulate or modulate [3,21-25]. Through
diverse mechanisms, EDCs can lead to serious reproductive,
developmental, and metabolic dysfunction in humans as well
as a wide range of animal and plant species [21,26-28]. Of
particular relevance to mammalian biology are EDCs that
are structurally similar to estrogen, and can therefore bind
to the ERs and interfere with the actions of the endogenous
steroid hormone [3]. Many EDCs are believed to have potential
estrogenicity and androgenicity. For example, recent studies
demonstrate that exposure of gestating female rats to
vinclozolin (an antiandrogenic compound) or methoxychlor
(an estrogenic compound) decreased spermatogenic capacity
of pups, which resulted in increased incidence of male infertility
and an epigenetic transgenerational phenotype involving a
number of diseases [26,29]. In our previous studies, several
phenol products, OP , NP and BPA, have an estrogenic or
progestogenic effect on immature rats or mice to induce
calbindin-D9k (CaBP-9k), a cytoplasmic calcium binding
protein [5,30-32]. We demonstrated that the absorption and
distribution of environmental estrogenic compounds in maternal
and neonatal uteri are extremely rapid, and these chemicals
can easily pass through the placenta during pregnancy or
breast milk during lactation to affect functions of neonatal
or fetal reproductive tissues [33-36]. In addition, genistein,
an ERβ ligand, enhanced CaBP-9k gene via ERα in the uterus
Figure 3. Confirmation of gene profiles by real-time
polymerase-chain reaction (PCR) analysis. Relative values of
expression of the altered genes quantified by real-time PCR
were shown in the graph, indicating the comparison of fold
change determined by real-time PCR analysis by 17β-estradiol
(E2, 10
−7 M) or bisphenol A (BPA, 10
−5 M) following 24 h
treatment in BG-1 cells. The representative genes included
RAB31_MEMBER RAS ONCOGENE FAMILY (U59877),
CYCLIN D1 (X59798), CYCLIN-DEPENDENT KINASE 4
(U37022), INSULIN-LIKE GROWTH FACTOR-BINDING
PROTEIN 4 (U20982), and ANTI-MULLERIAN HORMONE
(NM_000479). *P<0.05 vs. vehicle.1
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Table 2. Altered gene expressions involved in apoptosis, cancer, and cell cycle following treatment with E2 or BPA
Gene ID Gene name  E2-1h E2-8 h E2-24 h BPA-1 h  BPA-24 h
APOPTOSIS REGULATOR
U75285 APOPTOSIS INHIBITOR 4 (SURVIVIN) 0.985 1.185 1.942 1.193 1.477
D86970 TGFB1-INDUCED ANTI-APOPTOTIC FACTOR 1 1.411 1.109 1.791 1.182 0.746
AF043244 NUCLEOLAR PROTEIN 3  0.777 0.925 1.573 1.000 1.021
U13022 CASPASE 2_ APOPTOSIS-RELATED CYSTEINE PROTEASE (NEURAL PRECURSOR CELL 
EXPRESSED_ 0.896 0.537 1.460 0.800 1.284
U28015 CASPASE 5_ APOPTOSIS-RELATED CYSTEINE PROTEASE 1.007 0.753 1.447 1.553 0.891
AB011420 SERINE/THREONINE KINASE 17A  0.601 0.674 1.336 - -
AF057557 REGULATOR OF FAS-INDUCED APOPTOSIS 0.639 0.821 1.175 0.699 1.047
AF032457 BCL2-LIKE 11 (APOPTOSIS FACILITATOR) 1.126 0.662 0.618 - -
NM_001197 BCL2-INTERACTING KILLER (APOPTOSIS-INDUCING) 1.067 0.556 0.873 0.834 0.447
Y14039 CASP8 AND FADD-LIKE APOPTOSIS REGULATOR 1.377 1.387 0.830 0.584 0.704
U37547 APOPTOSIS INHIBITOR 1 1.655 2.036 0.551 0.656 0.490
U20536 CASPASE 6_ APOPTOSIS-RELATED CYSTEINE PROTEASE 0.789 2.499 2.216 - -
AL049703 PROGRAMMED CELL DEATH 8 (APOPTOSIS-INDUCING FACTOR) 1.478 1.133 0.467 1.072 0.523
NM_013229 APOPTOTIC PROTEASE ACTIVATING FACTOR 1.154 1.153 0.400 - -
CANCER
J03069 V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG 2 0.960 0.695 8.900 1.126 1.108
U59877 RAB31_ MEMBER RAS ONCOGENE FAMILY 1.325 3.259 4.151 0.977 2.969
K02276 V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG 5.710 5.407 2.911 1.145 1.914
U22376 V-MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG 1.407 3.088 2.714 1.284 1.895
J00277 V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG 1.019 1.391 2.616 1.168 1.160
NM_006325 RAN_ MEMBER RAS ONCOGENE FAMILY 0.916 0.860 2.200 1.019 1.312
U57092 RAB30_ MEMBER RAS ONCOGENE FAMILY 2.758 1.550 1.790 - -
M54915 PIM-1 ONCOGENE 1.296 1.899 1.525 1.463 1.650
U59878 RAB32_ MEMBER RAS ONCOGENE FAMILY 0.871 1.371 1.460 0.977 2.969
CELL CYCLE REGULATOR
X51688 CYCLIN A2 1.735 1.142 3.259 0.781 1.648
X59798 CYCLIN D1 (PRAD1: PARATHYROID ADENOMATOSIS 1) 2.377 1.485 2.470 0.773 1.378
M25753 CYCLIN B1 0.992 0.666 1.983 0.828 1.620
X78342 CYCLIN-DEPENDENT KINASE (CDC2-LIKE) 10 0.919 1.164 1.613 1.220 0.800
U37022 CYCLIN-DEPENDENT KINASE 4 0.898 4.016 1.593 0.970 1.788
L11669 TETRACYCLINE TRANSPORTER-LIKE PROTEIN 2.529 1.131 1.101 1.465 0.840
AF091433 CYCLIN E2 0.940 1.780 1.066 0.821 0.937
M92287 CYCLIN D3 1.999 1.349 1.045 1.168 1.143
NM_002134 HEME OXYGENASE (DECYCLING) 2 2.482 1.900 0.984 1.699 1.425
AF135162 CYCLIN I 2.233 1.164 0.562 0.365 1.609G
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Table 3. Altered gene expressions involved in signal transduction and nucleic acid binding following treatment with E2 or BPA
Gene ID Gene name E2-1 h E2-8 h E2-24 h BPA-1 h BPA-24 h
SIGNAL INDUCER
M30704 AMPHIREGULIN (SCHWANNOMA-DERIVED GROWTH FACTOR) 1.486 4.216 4.470 1.359 2.234
L27560 HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5 (IGFBP5) MRNA 0.799 1.060 2.621 1.268 1.351
U20982 INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 4 1.685 2.017 2.572 1.069 3.626
AF020044 STEM CELL GROWTH FACTOR; LYMPHOCYTE SECRETED C-TYPE LECTIN 1.350 1.335 2.347 - -
NM_000430 PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE_ ISOFORM IB_ ALPHA SUBUNIT 
(45KD) 1.228 1.650 2.101 - -
NM_016326 CHEMOKINE-LIKE FACTOR 3_ ALTERNATIVELY SPLICED 2.071 1.758 1.839 1.165 2.130
D86970 TGFB1-INDUCED ANTI-APOPTOTIC FACTOR 1 1.411 1.109 1.791 1.182 0.746
AF022795 TGF BETA RECEPTOR ASSOCIATED PROTEIN -1 1.446 1.398 1.725 1.359 1.862
X60957 TYROSINE KINASE WITH IMMUNOGLOBULIN AND EPIDERMAL GROWTH FACTOR 
HOMOLOGY DOMAINS258 0.304648 0.764 1.600 1.479 0.900
X02812 TRANSFORMING GROWTH FACTOR_ BETA 1 1.423 1.524 1.600 5.149 0.408
NM_000479 ANTI-MULLERIAN HORMONE 1.393 1.456 1.580 1.274 1.498
AF010187 FIBROBLAST GROWTH FACTOR (ACIDIC) INTRACELLULAR BINDING PROTEIN 1.212 1.440 1.487 1.190 1.838
AK000097 BRAIN AND REPRODUCTIVE ORGAN-EXPRESSED (TNFRSF1A MODULATOR) 1.283 1.768 1.363 0.799 0.907
AB000509 TNF RECEPTOR-ASSOCIATED FACTOR 5 0.580 1.244 1.326 1.076 0.890
J03071 CHORIONIC SOMATOMAMMOTROPIN HORMONE 2 1.576 1.350 1.312 1.161 1.210
L76687 GROWTH FACTOR RECEPTOR-BOUND PROTEIN 14 2.125 1.048 1.290 1.425 1.182
L76191 INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 1.979 3.932 1.201 0.661 1.730
U96876 INSULIN INDUCED GENE 1 0.610 0.825 1.146 0.933 0.866
X57025 INSULIN-LIKE GROWTH FACTOR 1 (SOMATOMEDIN C) 2.132 1.825 0.943 0.951 1.380
D10202 PLATELET-ACTIVATING FACTOR RECEPTOR 2.065 1.726 0.861 1.375 0.415
NUCLEIC ACID BINDING
X95648 EUKARYOTIC TRANSLATION INITIATION FACTOR 2B_ SUBUNIT 1 (ALPHA_ 26KD) 0.654 1.117 6.099 1.534 1.218
M90355 BASIC TRANSCRIPTION FACTOR 3-LIKE 2 2.567 1.380 4.975 0.732 1.193
M94046 MYC-ASSOCIATED ZINC FINGER PROTEIN (PURINE-BINDING TRANSCRIPTION FACTOR) 0.992 1.160 1.753 1.004 0.857
AF074723 RNA POLYMERASE II TRANSCRIPTIONAL REGULATION MEDIATOR (MED6_ S. CEREVISIAE_ 
HOMOLOG OF) 1.005 1.071 1.692 0.797 1.519
AC002544 EUKARYOTIC TRANSLATION INITIATION FACTOR 3_ SUBUNIT 8 (110KD) 1.263 1.926 1.622 1.147 1.799
U85658 TRANSCRIPTION FACTOR AP-2 GAMMA (ACTIVATING ENHANCER-BINDING PROTEIN 2 
GAMMA) 2.618 2.334 1.572 1.178 1.158
S75174 E2F TRANSCRIPTION FACTOR 4_ P107/P130-BINDING 0.985 1.215 1.440 0.997 1.798
M15353 EUKARYOTIC TRANSLATION INITIATION FACTOR 4E 2.423 0.861 1.331 1.652 1.100106 Kyung-A Hwang et al.
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of immature rats, suggesting that ERα may be a key mediator
in uterine CaBP-9k gene induction in immature rats [37]. 
Despite the prevalence of environmental EDCs, there are
few in vitro and in vivo methods for determining whether
or not a chemical is an EDC. These methods include the
receptor binding assay, reporter gene assay, and immature
rat uterotrophic assay. The reporter gene assay has many
benefits as a promising prescreening procedure, because this
assay could be performed as a rapid screening process to
detect an EDC mixed with thousands of other chemicals
[38]. Genetically-sensitive animal models, based on mice and
rats, could screen estrogenic chemicals for the induction of
endocrine-related genes. Efforts to identify the mechanisms
of endocrine disruption by estrogenic chemicals need to be
supported; these might find optimal tests for thousands of
chemicals potentially active in reproductive development and
function [39]. In our previous study, the EDC-induced
proliferation is mediated by a genomic effect through ERs
and estrogen response element (ERE), but EDC-activated
mitogen-activated protein kinase (MAPK) is unlikely involved
in the EDC-induced cell growth in estrogen-responsive ovarian
cancer cells [40]. In this study, we employed BG-1 cells (ovarian
cancer) model expressing ERs to detect the effect of E2 or
BPA by using microarray and real-time PCR analysis. The
genes related to apoptosis, cancer, cell cycle, signal transduction
and nucleic acid binding etc. were induced by E2 or BPA
treatment at different time points. These genes might be
universal estrogen-responsive genes among various tissues.
This compound exhibited a reasonable hierarchical clustering;
BPA resembled to E2.
To confirm the results of microarray analysis, we selected
several altered genes among them and further measured the
transcriptional levels of 5 altered genes including RAB31_
MEMBER RAS ONCOGENE FAMILY (U59877), CYCLIN D1
(X59798), CYCLIN-DEPENDENT KINASE 4 (U37022),
INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 4
(U20982), and ANTI-MULLERIAN HORMONE (NM_00479)
by real-time PCR following treatment with E2 (10
−7 M) or
BPA (10
−5 M) at 24 h in this cell model. In parallel with
their microarray results, the mRNA levels of these genes were
significantly induced by E2 or BPA treatment as shown in
Figure 3. These results indicate that BPA in parallel with E2
induced the transcriptional levels of E2-responsive genes in
an ER-positive BG-1 cells.
In conclusion, these microarray and real-time PCR results
indicate that BPA, a potential weak estrogen, may have
estrogenic effect by regulating E2-responsive genes in ER
positive BG-1 cells and BG-1 cells would be the best in vitro
model to detect these estrogenic EDCs.
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